caa a22 4500 606175970 CHVBK 20210128100745.0 cr unu---uuuuu 210128e20150201xx s 000 0 eng 10.1007/s00018-014-1756-3 doi (NATIONALLICENCE)springer-10.1007/s00018-014-1756-3 Steinbach Jill Department of Bioengineering, Center for Predictive Medicine, University of Louisville, 505 S. Hancock St., CTRB, Room 623, 40202, Louisville, KY, USA aut Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs [Elektronische Daten] [Jill Steinbach] Intravaginal delivery offers an effective option for localized, targeted, and potent microbicide delivery. However, an understanding of the physiological factors that impact intravaginal delivery must be considered to develop the nextgeneration of microbicides. In this review, a comprehensive discussion of the opportunities and challenges of intravaginal delivery are highlighted, in the context of the intravaginal environment and currently utilized dosage forms. After a subsequent discussion of the stages of microbicide development, the intravaginal delivery of proteins and oligonucleotides is addressed, with specific application to HSV and HIV. Future directions may include the integration of more targeted delivery modalities to virus and host cells, in addition to the use of biological agents to affect specific genes and proteins involved in infection. More versatile and multipurpose solutions are envisioned that integrate new biologicals and materials into potentially synergistic combinations to achieve these goals. Springer Basel, 2014 Intravaginal nationallicence Microbicides nationallicence Drug delivery nationallicence Gene delivery nationallicence Protein delivery nationallicence Sexually transmitted infection (STI) nationallicence HIV nationallicence HSV nationallicence Intravaginal ring (IVR) nationallicence Nanoparticles nationallicence Ab : Antibody nationallicence ACV : Acyclovir nationallicence AIDS : Acquired immunodeficiency syndrome nationallicence API : Active pharmaceutical ingredient nationallicence ARV : Antiretroviral nationallicence AsiCs : Aptamer-siRNA chimeras nationallicence BSA : Bovine serum albumin nationallicence CAP : Cellulose acetate phthalate nationallicence CCR : Chemokine receptor nationallicence CD4 : Cluster of differentiation four nationallicence CD4+/− : Cluster of differentiation four positive or negative nationallicence CEA : Carcinoembryonic antigen nationallicence CMIS : Common mucosal immune system nationallicence CXCR4 : Chemokine (C-X-C motif) receptor four nationallicence DC : Dendritic cell nationallicence DC-SIGN(R) : Dendritic cell-specific-ICAM-grabbing non-integrin (receptor) nationallicence ENF : Enfuvirtide nationallicence EVAc : Ethylene-co-vinyl acetate nationallicence FcRN : Fc neonatal receptor nationallicence FTC : Emtricitabine nationallicence gP : Glycoprotein nationallicence GRFT : Griffithsin nationallicence HAART : Highly active antiretroviral treatment nationallicence hCG : Human chorionic gonadotropin nationallicence HIV : Human immunodeficiency virus nationallicence HSPG : Heparan sulfate proteoglycan nationallicence HSV : Herpes simplex virus nationallicence ICAM : Intercellular adhesion molecule nationallicence IVR : Intravaginal ring nationallicence LDH-C4 : Lactate dehydrogenase C4 nationallicence LFA : Lymphocyte function-associated antigen nationallicence mAb : Monoclonal antibody nationallicence MZC : MIV-150, zinc acetate, and carrageenan nationallicence N9 : Nonoxynol-9 nationallicence NP : Nanoparticle nationallicence NRTI : Nucleoside reverse transcriptase inhibitor nationallicence NNRTI : Non-NRTIs nationallicence OVA : Ovalbumin nationallicence pDNA : Plasmid DNA nationallicence PI : Protease inhibitor nationallicence PLGA : Poly(lactic-co-glycolic acid) nationallicence PrEP : Pre-exposure prophylaxis nationallicence PSS : Polystyrene sulfonate nationallicence PU : Polyurethane nationallicence RNAi : RNA interference nationallicence siRNA : Short interfering ribonucleic acid nationallicence STD : Sexually transmitted disease nationallicence STI : Sexually transmitted infection nationallicence TDF : Tenofovir disoproxil fumarate nationallicence TFV : Tenofovir nationallicence VCF : Vaginal contraceptive film nationallicence Cellular and Molecular Life Sciences Springer Basel 72/3(2015-02-01), 469-503 1420-682X 72:3<469 2015 72 18 https://doi.org/10.1007/s00018-014-1756-3 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 review-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00018-014-1756-3 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Steinbach Jill Department of Bioengineering, Center for Predictive Medicine, University of Louisville, 505 S. Hancock St., CTRB, Room 623, 40202, Louisville, KY, USA aut NATIONALLICENCE 773 0- Cellular and Molecular Life Sciences Springer Basel 72/3(2015-02-01), 469-503 1420-682X 72:3<469 2015 72 18